112 related articles for article (PubMed ID: 21950209)
1. Predicting tumour response to anti-HER1 therapy using medical imaging: a literature review and in vitro study of [18F]-FDG incorporation by breast cancer cells responding to cetuximab.
Smith TA; Cheyne RW
Br J Biomed Sci; 2011; 68(3):158-66. PubMed ID: 21950209
[TBL] [Abstract][Full Text] [Related]
2. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.
Cheyne RW; Trembleau L; McLaughlin A; Smith TA
Nucl Med Biol; 2011 Apr; 38(3):339-46. PubMed ID: 21492782
[TBL] [Abstract][Full Text] [Related]
3. Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
Cooper AC; Fleming IN; Phyu SM; Smith TA
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1523-32. PubMed ID: 25579456
[TBL] [Abstract][Full Text] [Related]
4. Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
Sharma RI; Smith TA
J Nucl Med; 2008 Aug; 49(8):1386-94. PubMed ID: 18632807
[TBL] [Abstract][Full Text] [Related]
5. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
Fleming IN; Andriu A; Smith TA
Breast Cancer Res Treat; 2014 Apr; 144(2):241-8. PubMed ID: 24522376
[TBL] [Abstract][Full Text] [Related]
6. EGF receptor stimulation shifts breast cancer cell glucose metabolism toward glycolytic flux through PI3 kinase signaling.
Jung KH; Lee EJ; Park JW; Lee JH; Moon SH; Cho YS; Lee KH
PLoS One; 2019; 14(9):e0221294. PubMed ID: 31532771
[TBL] [Abstract][Full Text] [Related]
7. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2.
Kang F; Ma W; Ma X; Shao Y; Yang W; Chen X; Li L; Wang J
J Nucl Med; 2014 Mar; 55(3):439-45. PubMed ID: 24504055
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
McLarty K; Fasih A; Scollard DA; Done SJ; Vines DC; Green DE; Costantini DL; Reilly RM
J Nucl Med; 2009 Nov; 50(11):1848-56. PubMed ID: 19837760
[TBL] [Abstract][Full Text] [Related]
9. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
10. Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.
Smith TA; Appleyard MV; Sharp S; Fleming IN; Murray K; Thompson AM
Cancer Chemother Pharmacol; 2013 Feb; 71(2):473-80. PubMed ID: 23178956
[TBL] [Abstract][Full Text] [Related]
11. Influence of resistance to 5-fluorouracil and tomudex on [18F]‑FDG incorporation, glucose transport and hexokinase activity.
Law AA; Collie-Duguid ES; Smith TA
Int J Oncol; 2012 Jul; 41(1):378-82. PubMed ID: 22576694
[TBL] [Abstract][Full Text] [Related]
12. 99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to cetuximab therapy.
Jung KH; Choe YS; Paik JY; Lee KH
J Nucl Med; 2011 Sep; 52(9):1457-64. PubMed ID: 21849406
[TBL] [Abstract][Full Text] [Related]
13. Glucose-6-phosphatase Expression-Mediated [
Kim MJ; Lee CH; Lee Y; Youn H; Kang KW; Kwon J; Alavi A; Carlin S; Cheon GJ; Chung JK
Mol Imaging Biol; 2019 Oct; 21(5):917-925. PubMed ID: 30719695
[TBL] [Abstract][Full Text] [Related]
14. A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.
Berger AK; von Gall C; Abel U; Delorme S; Kloor M; Ose J; Weber TF; Stange A; Haag GM; Haberkorn U; Lordick F; Jäger D
BMC Cancer; 2012 Mar; 12():108. PubMed ID: 22439666
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
[TBL] [Abstract][Full Text] [Related]
17. Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging.
Wang K; Wang K; Li W; Huang T; Li R; Wang D; Shen B; Chen X
Acta Radiol; 2009 Dec; 50(10):1095-103. PubMed ID: 19922304
[TBL] [Abstract][Full Text] [Related]
18. PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma.
Sadri K; Ren Q; Zhang K; Paudyal B; Devadhas D; Rodeck U; Thakur M
Nucl Med Commun; 2011 Jul; 32(7):563-9. PubMed ID: 21572364
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
20. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
Kelly CJ; Hussien K; Muschel RJ
Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
